Here’s a very thoughtful summary of the current RSV market, which is getting more crowded and more interesting by the minute. Michale Gibney reports on Merck’s new monoclonal antibody for young children and how it fits into what is becoming a rather competitive landscape. Gives you a nice perspective on vaccines and monoclonal antibodies for adults and for infants. While AREXVY and ABRYSVO have made headway into the adult market no new vaccine has yet cracked the pediatric indication. Moderna’s latest shot on goal took a step back last week, when a feint signal seemed to appear in one of its clinical trials.
When we started writing Bad Pharma over four years ago, none of these new treatments were licensed. We knew it was an area of interest for many companies but never could have predicted the number of new products to have come to market over that time period. Pretty lucky timing